Digestive issues were reported by 76% of respondents aged 35 and over in a global survey of 17,494 women, level with sleep problems and above anxiety. Yet the three most widely used menopause rating scales contain no digestive item at all. That absence, rather than any single statistic, is the most solid thing this article has to offer.
It also has to be honest about something less comfortable: the evidence connecting perimenopause to gut symptoms is genuinely thin, and several widely shared figures do not mean what they appear to.
What is actually missing from the checklists?
The Menopause Rating Scale has exactly 11 items across three subscales. It is formally validated and translated into many languages, and it is the instrument the global survey above drew its symptom list from. It contains no digestive, gastrointestinal, bloating, constipation or reflux item.
Neither does the Greene Climacteric Scale, with 21 items across anxiety, depression, somatic, vasomotor and sexual function domains. Neither does MENQOL.
So if you have filled in a menopause questionnaire and it never asked about your gut, that was not an oversight by your clinic. The instrument does not contain the question. Three named, standard, validated instruments do not ask.
A precise version of that claim matters. This is verified for the Menopause Rating Scale, the Greene Climacteric Scale and MENQOL. It is not a claim about every questionnaire in every hospital, which would be a broader statement than anyone has checked.
How strong is the evidence, really?
Weaker than the confident articles suggest, and this is where most coverage quietly stops being useful.
A frequently cited UK survey reports that 94% of participants had digestive symptoms, with bloating at 77%, and that 82% said symptoms began or worsened at perimenopause or menopause. Those numbers are real, but three things about them need stating. It is a conference poster rather than a peer reviewed paper. The survey was distributed through a commercial menopause education platform, so respondents were people already engaged with menopause content. And the researcher subsequently partnered with a probiotic company on a follow up study recruiting from the same audience.
Set against that, population level data runs the other way:
| Measure | What population data shows |
|---|---|
| IBS prevalence by age (Rome IV) | 5.3% at ages 18 to 39, 3.7% at 40 to 64, 1.7% at 65 and over. It falls with age |
| Weekly bloating (Rome Foundation, 51,425 people) | 23.4% of women against 12.2% of men, but prevalence declines with age |
| Constipation, longitudinal (Seattle Midlife Women’s Health Study, 291 women followed to 2013) | Menopause transition stage was not an independent predictor |
| Abdominal pain, same study | Severity decreased with advancing age |
| Evidence base overall (2025 scoping review of 122 studies) | Only 22 studies had gastrointestinal symptoms in peri or postmenopause as a primary focus. The review found the evidence thin and inconsistent |
Two of those rows can be read at source. The bloating figures come from the Rome Foundation Global Epidemiology Study, published in Gastroenterology in 2023, which surveyed 51,425 people in 26 countries and found 17 per cent of the whole sample reporting bloating at least weekly. The evidence base row is the 2025 scoping review of research on gastrointestinal symptoms in natural peri and postmenopause by Shaw, Abbott and Pettinger. The IBS by age figures and the Seattle Midlife Women’s Health Study were not rechecked this week.
The tension here is real and unresolved. Cross sectional surveys where people attribute their own symptoms show a strong perimenopause link. Longitudinal studies that measure the same women over years mostly do not find one. Both types of study are legitimate, and they disagree.
If you searched something like my IBS started at 45, the honest answer is that population data shows IBS is predominantly diagnosed before 35 and becomes less common with age. That does not mean nothing changed for you. It means the tidy explanation available online is not well supported.
What about the hormone explanation?
There is no verified causal pathway from oestrogen or progesterone change to bloating, reflux or altered bowel habit. The 2025 scoping review states explicitly that the evidence is insufficient to determine whether hormonally triggered microbial changes contribute.
One finding worth knowing because it runs opposite to the popular framing: a meta analysis published in Menopause found menopausal hormone therapy associated with higher odds of gastro oesophageal reflux disease, not lower. That is an association rather than a demonstration of cause, and it is reported here only because the reverse is so often assumed.
A precision this page lacked when first published: the pooled adjusted odds ratio of 1.41 is the figure for oestrogen use specifically, drawn from studies covering more than a million participants. The same analysis reported 1.39 for progestogen use, from two studies, and 1.16 for combined hormone therapy, according to The Menopause Society’s announcement of the paper, checked on 13 September 2026. The frequently asked questions below still give 1.41 for hormone therapy in general, which is the oestrogen figure.
What is genuinely worth acting on
Two things, and neither of them involves buying anything.
First, gastrointestinal symptoms do vary across the menstrual cycle in ways that are documented. Recording when symptoms occur relative to your cycle produces information that a general description does not, and what to actually write down in a perimenopause symptom diary sets out a record a doctor can use.
Second, and more important, some symptoms should not be attributed to hormones at all. NICE guideline CG61 on irritable bowel syndrome in adults lists red flags for referral in suspected IBS: unintentional and unexplained weight loss, rectal bleeding, and a change in bowel habit to looser or more frequent stools persisting for more than six weeks in someone over 60. Bloating has its own threshold too: NICE asks GPs to test for ovarian cancer when it is persistent or frequent, particularly more than 12 times a month, and we set out how that frequency rule for ovarian cancer symptoms works. Separately, difficulty swallowing warrants a suspected cancer pathway referral at any age under NICE NG12 on suspected cancer, with no age threshold.
If any of those apply, the perimenopause question can wait.
This article names no probiotic, supplement, elimination diet or gut protocol, and that is deliberate. It is where the evidence is weakest and where most of the commercial pressure sits. Anything persistent belongs in front of a doctor rather than being managed from a website.
What to say at an appointment
- When the symptoms started, and what specifically changed.
- Whether they track with your cycle, which requires a few months of notes to answer.
- What else changed around the same time, including sleep, mood and periods.
- That you would like the red flag possibilities excluded, naming them if that is easier than describing them.
- That you are aware the evidence linking this to perimenopause is contested, which tends to make for a better conversation than arriving with a conclusion.
The Women’s Health Concern factsheet on digestive health and menopause, published in July 2025 by the patient arm of the British Menopause Society, is a reasonable place to read further. For the wider pattern of under-recognised symptoms, see perimenopause fatigue, and if you are being told your age rules this out, being told you are too young.
Frequently asked questions
Does perimenopause cause bloating?
No causal pathway has been established. Digestive issues were reported by 76% of respondents aged 35 and over in a global survey, but longitudinal studies following the same women over years have mostly not found menopause transition stage to be an independent predictor of digestive symptoms. The evidence is genuinely contested.
Why do menopause questionnaires never ask about digestion?
Because the standard instruments do not contain the question. The Menopause Rating Scale has 11 items and no digestive item. The Greene Climacteric Scale and MENQOL also lack one. This is verified for those three named instruments.
Can perimenopause cause IBS?
Population data shows IBS prevalence falls with age, from 5.3% at 18 to 39 down to 3.7% at 40 to 64, and IBS is predominantly diagnosed before 35. There is no population level rise at midlife, so the common framing that IBS starts in perimenopause is not well supported.
Is the 94% bloating figure reliable?
Treat it carefully. It comes from a conference poster rather than a peer reviewed paper, the survey was distributed through a commercial menopause platform so respondents were already engaged with the topic, and the researcher later partnered with a probiotic company on follow up work recruiting from the same audience.
Does HRT help digestive symptoms?
This article does not cover hormone therapy as an option, and the evidence does not point the way people assume. A meta analysis found menopausal hormone therapy associated with higher odds of gastro oesophageal reflux disease, with a pooled adjusted odds ratio of 1.41. Discuss any treatment question with a doctor.
When should digestive symptoms be checked urgently?
NICE CG61 lists unintentional and unexplained weight loss, rectal bleeding, and a change in bowel habit to looser or more frequent stools persisting beyond six weeks in someone over 60. Difficulty swallowing warrants a suspected cancer pathway referral at any age under NICE NG12.
This article is general information, not medical advice, and is not a substitute for care from a qualified healthcare professional. Speak to your doctor about your own situation.
Leave a Reply